Conference Preview: American Urological Association 2025

The American Urological Association’s (AUA) Annual Meeting kicks off in Las Vegas, Nevada on Saturday, April 26, 2025. Spanning 4 days, the conference will feature several noteworthy Practice-Changing sessions, clinical trials in progress, guideline updates, and more.

The meeting will take place from April 25-29, 2025 in Las Vegas, Nevada.

The agenda for this year’s meeting will provide updates on key topics in bladder cancer, prostate cancer, sexual health, benign prostatic hyperplasia (BPH), and more. The Urology Times® editorial team will be on-site throughout the meeting providing written coverage of practice-shifting data as well as interviews with key experts.

Take a look below at what can be expected throughout this year’s meeting. You can keep up with Urology Times’ comprehensive coverage here.

Notable Interviews

On-site interviews with the Urology Times team are planned with a variety of featured guests, some of which include:

Melissa R. Kaufman, MD, PhD, FACS, who will share insights on the AUA/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Genitourinary Syndrome of Menopause guideline, which will be unveiled at this year’s annual meeting. Kaufman is the division chief of reconstructive urology and pelvic health at Vanderbilt University Medical Center in Nashville, Tennessee.

Neal Shore, MD, FACS, who will highlight findings from the phase 3 CREST trial (NCT04165317) of sasanlimab plus BCG vs BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC). Shore is the medical director for the Carolina Urologic Research Center in Myrtle Beach, South Carolina.

Joseph Jacob, MD, MCR, who will outline findings from the first of 2 P2 presentations on TAR-200, an intravesical delivery system that works by providing sustained low doses of localized gemcitabine via insertion into the bladder. Jacob is an associate professor of urology at Upstate Medical University in Syracuse, New York.

Felix Guerrero-Ramos, MD, PhD, FEBU, who will share data from cohort 4 of the SunRISe-1 trial (NCT04640623) evaluating TAR-200 in a cohort of patients with BCG-unresponsive, papillary disease only, high-risk NMIBC. Guerrero-Ramos is an attending urologist at Hospital Universitario 12 de Octubre in Madrid, Spain.

Seth Bechis, MD, who will outline results from a randomized clinical trial of ureteral stent placement vs stent omission following ureteroscopy for renal stones. Bechis is an associate professor of urology at the University of California, San Diego Health.

Bilal Chughtai, MD, who will walk through data from the pivotal trial of the Butterfly Prostatic Retraction Device in men with lower urinary tract symptoms secondary to BPH. Chughtai is the chief of urology at Plainview Hospital and an associate professor of urology at Northwell Health in Syosset, New York.

From the EIC

Urology Times’ co-Editor-in-Chief Gopal Badlani, MD, FACS, FRCS, shared his thoughts on what to look out for at this year’s meeting.

He said, “The annual AUA meeting continues to be an ocean of knowledge with many new features. Some of these include, "The patient perspective", "Clinical trials in progress" "Global getaway posters for International submissions" and at the conclusion, "Key takeaways: thought-provoking discussions with the experts.

“The content of note is new innovation in [interstitial cystitis], including highlights of the global consensus in the [Society of Infection and Inflammation] session on Monday. The BPH wars on the best [minimally invasive therapy] continue, as do the controversy in stone disease, [with the session: ‘To stent or not to stent.’ [There is also] an interesting course, ‘Practical AI for Practicing Urologists,’” Badlani added.

Additional reactions from urologists

Several other urologists shared what they are most looking forward to at this year’s meeting. See their insights below!

Suzanne B. Merrill, MD, FACS: "I always look forward to our annual AUA meeting. It is one of the biggest and most respected gatherings in the field of urology. Within a mere 4 days, I am able to get critical updates on potentially practice-changing clinical trials, learn from experts discussing advancements and paradigm shifts in our field during plenary and crossfire sessions, and be exposed to cutting edge technology and pharma in our Expo Hall. On top of this goldmine of learning, the AUA is always a wonderful opportunity to catch up with respected mentors and cherished colleagues."

Dean Elterman, MD, MSc, FRCSC: “This year's AUA will have lots of exciting research in the field of functional urology. Several of the novel BPH stents will be presenting their findings, along with longer-term data on Optilume BPH, Aquablation, and enucleation techniques. Additionally, the Innovation Nexus on Friday will highlight up-and-coming technologies in the field.”

Stephen A. Boorjian, MD: “[The] AUA annual meeting represents a fantastic opportunity to learn about the absolute most cutting-edge treatments for our patients. I am particularly excited to hear updates on active non–muscle invasive bladder cancer clinical trials, as the landscape of treatments for these patients continues to expand. Similarly, I look forward to learning more in depth about recently released AUA Guidelines through plenary session programs.”

Stacy Loeb, MD, MSc, PhD (Hon): “I am excited to hear about the latest research in urology, particularly how new technologies and artificial intelligence can be used to improve our clinical practice. It is also a wonderful opportunity to see friends and colleagues from around the world and establish new research collaborations.”

See also our coverage on notable P2 presentations in urologic oncology here, as well as trials in progress to keep an eye on here.